Environmental Impact Acquisition Corp.

Canaccord Genuity Acts as Exclusive Financial Advisor to Environmental Impact Acquisition Corp. (Nasdaq: ENVI), a Canaccord Genuity Sponsored SPAC, on its Merger with GreenLight Biosciences Holdings, Inc. (Nasdaq: GRNA) 

Canaccord Genuity is pleased to announce that it has advised Environmental Impact Acquisition Corporation (NASDAQ: ENVI), a publicly-traded special purpose acquisition company, on its business combination with Greenlight Biosciences. The business combination and merger was approved in a shareholder vote held Feb. 1, 2022, with 80.7% of shareholders participating in the vote and 78.6% voting in favor of the combination.

In connection with the closing of the merger, the company will change its name to GreenLight Biosciences Holdings, public-benefit corporation, and the combined company’s shares of Class A common stock and public warrants are now trading on the Nasdaq Capital Markets exchange, under the ticker symbols “GRNA” and “GRNA.WS,” respectively.

Investors in GreenLight Biosciences include Serum Life Sciences, Fall Line Capital, Viceroy Capital, S2G Ventures, Cormorant Asset Management, Morningside Venture Investments, Hudson Bay Capital, BNP Paribas Ecosystem Restoration Fund, The Jeremy and Hannelore Grantham Environmental Trust, Continental Grain Company, Pura Vida Investments LLC, Xeraya Capital, and MLS Fund II/Spruce.

GreenLight Biosciences aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. The Company's RNA platform allows it to research, design, and manufacture for human, animal, and plant health. In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company’s platform is protected by numerous patents, and applications for its products under development include vaccine development, pandemic preparation, crop management, and plant protection. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. The GreenLight Biosciences team values diversity, inclusion, and equality and uses collaboration to remain scientifically imaginative and passionately focused on making a difference in the world.

Canaccord Genuity, with a team led by Dan Coyne, Marc Marano, Jennifer Pardi, Brian O’Connor, Andy Viles, Larissa Teipner, Tom Gabel, David Istock, Eugene Rozelman, Chris DiPietro, and Mike Wright, served as an exclusive financial advisor to Environmental Impact Acquisition Corp.